Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:
“A new cohort study published in JAMA Oncology suggests that ablative radiation therapy (A-RT) may offer a nonoperative alternative for technically resectable pancreatic ductal adenocarcinoma (PDAC) in patients with high surgical risk.
25 patients with resectable PDAC (median age 80, many with poor performance status) received A-RT (>97.5 Gy BED).
2-year outcomes:Overall survival: 43.7%
Local progression: 20.8%
No grade 4+ toxicity
Implication: A-RT could be a viable option for patients where surgery is not feasible due to age or comorbidities.”
Title: Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy
Authors: Marsha Reyngold, Joshua D. Schoenfeld, Eileen M. O’Reilly, Anna M. Varghese, Charlie White, Melissa Zinovoy, Paul B. Romesser, Abraham J. Wu, Carla Hajj, John J. Cuaron, Danny N. Khalil, Wungki Park, Wei Lu, Zhigang Zhang, Kenneth H. Yu, Luis A. Diaz Jr, Christopher H. Crane
More posts featuring Elvina Almuradova.